Nebuliser in every home
The quiet medicalisation of middle-class India.
Walk into the living rooms of India’s Tier-1 and Tier-2 cities today. Next to the air fryer and the water purifier, you’ll increasingly find a new appliance humming quietly in the corner — the home nebuliser.
What was once reserved for hospital emergency departments is now a domestic fixture. And for those of us in chest medicine and paediatrics, this is not a healthcare victory. It is a warning sign.
The Mist Has a Price
There’s a reason the nebuliser has conquered the middle-class home: it feels serious. The machine whirs. A white mist rises. Ten minutes pass. The parent feels they have done something.
Meanwhile, the Metered Dose Inhaler (MDI) — the gold standard of respiratory care, endorsed by every global guideline — collects dust in the medicine cabinet. In our cultural imagination, “the pump” signals weakness. Permanence. Addiction. Stigma.
So families choose the mist. And in doing so, they often deliver the exact same molecule — just less efficiently, with greater systemic absorption, and with a false sense of security that can delay life-saving care.
What the Evidence Actually Says
Let me be direct about the pharmacology.
For the vast majority of patients — both children and adults — with mild-to-moderate asthma or wheezing, a pressurised MDI (pMDI) with a Valved Holding Chamber (spacer) is clinically superior to a home nebuliser.
Here’s why:
- Targeted delivery: A spacer enables the patient to inhale at their own pace, achieving deeper lung deposition. Nebulisation — especially with shallow, distressed breathing — often wastes a significant proportion of the dose.
- Speed: An MDI + spacer takes under two minutes. A nebuliser takes ten to fifteen.
- Safety profile: Nebulisers frequently require higher beta-agonist doses to achieve the same bronchodilation — increasing systemic side effects like tremors and tachycardia.
- Hygiene risk: Home nebulisers that are inadequately cleaned become bacterial reservoirs, adding infection risk to an already compromised airway.
The evidence is not ambiguous. For acute asthma, an MDI plus spacer is as effective as a nebuliser in clinical trials — in both children and adults.
The Hero Nobody Respects: The Spacer
If there’s a tragedy at the heart of this trend, it’s the fate of the spacer — the most underused, undervalued device in Indian paediatrics.
Parents often look at it with puzzlement. “This plastic tube? For my child’s breathing?”
Yet this “plastic tube” is a precision aerosol-holding chamber that transforms a puff of medicine into targeted, deep-lung therapy. Dismissing it as a toy is like dismissing a surgical instrument because it doesn’t look dramatic enough.
And here is the hard truth for all of us as healthcare professionals: every time we “allow” home nebulisation for a routine viral-induced wheeze without first teaching spacer technique, we validate the patient’s fear of inhalers. We become complicit in the very phobia we should be dismantling.
Why does this happen? Because the path of least resistance is the compressor. Nebulisation is easier to prescribe, easier to explain, and for some supply chains, easier to sell. The spacer requires teaching, demonstration, and follow-up. That five-minute investment is exactly what we must reclaim.
When Nebulisation Is Genuinely Appropriate
The nebuliser is not the villain. Indiscriminate application is.
There are clear, evidence-based indications for nebulisation: - Life-threatening exacerbations where inspiratory flow is too poor for a spacer - Specific formulations unavailable as MDI or DPI (e.g., mucolytics in cystic fibrosis, certain antibiotics) - Physical or cognitive limitations that preclude spacer use — severe neuromuscular disorders, advanced dementia - Emergency room stabilisation requiring continuous or high-dose delivery under monitoring
Using it for a rattly winter chest, a common cold, or as a substitute for a daily ICS preventer regime is not advanced medical management. It is medicalisation of the mundane — and it carries a real public health cost.
The Cycle We Are Creating
When a family owns a home nebuliser, their relationship with respiratory disease changes — and not for the better.
They begin to manage crises rather than prevent them. They treat attacks at home and delay hospital presentation when oxygen saturations are falling. They rely on short-acting bronchodilators (SABA/SAMA) while quietly under-treating the underlying airway inflammation. Daily inhaled corticosteroids — the drugs that actually change the trajectory of the disease — get abandoned.
The mist provides comfort. The disease continues to progress underneath it.
I have seen a ten-year-old receive salbutamol nebulisation every time she catches a cold — parents beaming with pride at how “proactive” they are being. I have seen a family physician nebulise a child at every clinic visit, until the family simply bought the machine and started doing it themselves.
These are not edge cases. They are the quiet norm in thousands of homes across India.
Our responsibility as doctors and as an industry
We must stop treating the “nebuliser in every home” trend as an innocent quirk of patient preference. It is a public health challenge — and we have contributed to it.
Our responsibility is to:
- Demystify the inhaler. The pump is not a sign of weakness. It is a tool for freedom, precision, and long-term lung health.
- Reintroduce the spacer as the sophisticated medical device it is. Demonstrate it. Teach it. Follow up on technique.
- Have the difficult five-minute conversation. Explain that the visible mist is not a marker of efficacy. Explain that a well-used spacer actually changes the trajectory of their child’s lung health.
- Recognise our own role in the supply chain of over-nebulisation — institutional inertia, time pressure, and commercial forces all push in the same direction. Awareness is the first counter.
The sound of caring
The hum of the home compressor has come to represent, for millions of families, the sound of caring for a child. Our task — urgent, unsexy, and essential — is to replace that sound with something better: the quiet confidence of a patient who knows how to use their inhaler.
It is time to move the “hospital” out of the living room and put the science back into the hands of the patient.